Patients with advanced multiple myeloma (MM) often have increased osteolytic activity of osteoclasts and impaired osteogenesis by osteoblasts, resulting in osteolytic bone lesions that increase the risk of skeletal-related events (SREs) including pathologic fracture, the need for radiotherapy or surgery to bone, and spinal cord compression. Such SREs are potentially life-limiting, and can reduce patients’ functional independence and quality of life. Bisphosphonates (e.g., oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM. Extensive clinical experience demonstrates that bisphosphonates are generally well tolerated, and common adverse events are typically mild and manageable. Studies are ongoing to optimize the timing and duration of bisphosphonate therapy in patients with bone lesions from MM
Keywords : administration & dosage,Animals,Bone and Bones,Bone Density,Bone Density Conservation Agents,Bone Neoplasms,Breast Neoplasms,Clinical Trials as Topic,Clodronic Acid,complications,Diphosphonates,drug effects,drug therapy,etiology,Female,Humans,Imidazoles,Mice,Multiple Myeloma,Osteolysis,Pain,Pamidronate,pathology,prevention & control,Quality of Life,radiotherapy,Risk Factors,Spinal Cord,Spinal Cord Compression,surgery,therapeutic use,therapy,Zoledronic Acid,, Role,Bisphosphonate,Therapy, knee pain injection therapy
Date of Publication : 2011 Feb
Authors : Terpos E;Dimopoulos MA;Berenson J;
Organisation : Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece. eterpos@med.uoa.gr
Journal of Publication : Crit Rev Oncol Hematol
Pubmed Link : https://www.ncbi.nlm.nih.gov/pubmed/21353176
The London Spine Unit : Harley Street UK. Specialists in Cutting Edge Technologies for Spinal Surgery
English
Arabic
Chinese (Simplified)
Russian
Spanish
Urdu